Welcome to our dedicated page for Absci news (Ticker: ABSI), a resource for investors and traders seeking the latest updates and insights on Absci stock.
Absci Corporation develops generative AI-designed biologic therapeutics as a clinical-stage biopharmaceutical company. News about ABSI centers on its Integrated Drug Creation platform, internal prolactin and prolactin receptor (PRLR) programs, and clinical development of ABS-201, an anti-PRLR antibody being developed for androgenetic alopecia and endometriosis.
Recurring updates cover HEADLINE trial safety, tolerability and pharmacokinetic disclosures, preclinical pipeline additions such as ABS-202, business and operating results, clinical advisory activity, healthcare conference participation, executive leadership changes, and Nasdaq inducement equity grants.
Absci (Nasdaq: ABSI) will participate in the 25th Annual Needham Virtual Healthcare Conference.
Management is scheduled for a fireside chat on April 16, 2026 at 1:30 p.m. ET (10:30 a.m. PT). A live and archived webcast will be available on the company's investor relations website.
Absci (Nasdaq: ABSI) reported Q4 and full-year 2025 results and operational updates including dosing three SAD cohorts of ABS-201 in the Phase 1/2a HEADLINE trial with favorable emerging safety data and human ex vivo evidence of hair-growth activity.
Cash and marketable securities were $144.3M at year-end, sufficient to fund operations into H1 2028 per the company.
Absci (NASDAQ: ABSI) launched an Endometriosis Advisory Board to guide clinical development of ABS-201, an anti‑prolactin receptor antibody designed as a non‑hormonal therapy for endometriosis. The board includes experts from Yale, UCSF, Duke, and Mayo Clinic. Absci anticipates Phase 2 start in Q4 2026 and an interim readout in H2 2027. ABS-201 is formulated for subcutaneous self-administration and showed an extended half-life in non‑human primates, aiming to treat lesions without suppressing ovulation or fertility.
Absci (Nasdaq: ABSI) granted a 650,000-share non-statutory stock option to Dr. Ransi Somaratne as an inducement for his employment as Chief Medical Officer on March 3, 2026.
The option has a $2.57 exercise price (closing price on March 3, 2026), a 10-year term, and vests over four years (25% at one year, remainder in 36 monthly installments).
Absci (Nasdaq: ABSI) appointed Ransi Somaratne, M.D., FACC, MBA as Chief Medical Officer effective March 3, 2026 to lead clinical development of its AI-designed therapeutics, including flagship ABS-201. Chief Innovation Officer Andreas Busch, Ph.D. will retire March 31, 2026 and transition to co-chair Absci’s Scientific Advisory Board.
Dr. Somaratne joins from Vertex and has prior leadership at BioMarin and Amgen, with experience on Roctavian, Repatha, and Journavx.
Absci (Nasdaq: ABSI) will report business updates and fourth-quarter and full-year 2025 financial and operating results after market close on March 24, 2026.
A webcast and live audio conference call will begin at 4:30 p.m. ET (1:30 p.m. PT), with the live stream and archived replay available via the company’s investor relations site at investors.absci.com.
Absci (Nasdaq: ABSI) will participate in multiple investor conferences in March 2026, including TD Cowen, Leerink Partners, Jefferies Biotech on the Beach, and KeyBanc Healthcare Forum. The company will host fireside chats and 1x1 meetings, with select webcasts available on its investor relations site.
Live and archived webcasts of the TD Cowen, Leerink, and KeyBanc fireside chats will be posted at investors.absci.com, and specific session dates and times are listed for investors.
Absci (Nasdaq: ABSI) will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco. Management is scheduled to present on Wednesday, January 14, 2026 at 3:45 p.m. PT (6:45 p.m. ET). Interested parties can watch a live and archived webcast via the company's investor relations site at investors.absci.com.
The presentation will cover the company's clinical-stage programs and AI-driven therapeutic platform; a webcast will be available for on-demand viewing after the presentation.
Absci (NASDAQ: ABSI) reported new human ex vivo data for ABS-201, an anti‑PRLR antibody, showing it prolongs anagen, stimulates hair matrix keratinocyte proliferation, increases follicular IGF1 and FGF7, and preserves/expands the K15+/CD34+ stem and progenitor pool in organ‑cultured full‑thickness human scalp. Findings suggest ABS-201 may reverse follicle miniaturization by promoting vellus‑to‑terminal reconversion and neutralizing intrafollicular prolactin signaling. The full dataset was presented at Absci’s ABS-201 KOL seminar on Dec 11, 2025 and slides were posted to investor relations.
Absci (Nasdaq: ABSI) announced a partnership with U.S. soccer legend Landon Donovan to raise awareness of androgenetic alopecia (AGA) and the emotional impact of hair loss. Donovan will speak about his personal experience at Absci’s virtual Key Opinion Leader seminar on December 11, 2025, providing patient perspective to guide development of the company’s investigational antibody ABS-201. Absci said it will present additional human ex vivo data supporting the PRLR mechanism of action and discuss the anticipated clinical development path and market opportunity for ABS-201.
The collaboration aims to destigmatize hair loss, highlight unmet treatment needs, and center patient voice in Absci’s AI-driven drug design efforts.